Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

L. Kappos; M.S. Freedman; C.H. Polman; G. Edan; H.P. Hartung; D. Miller; X. Montalban; F. Barkhof; E.W. Radu; C. Metzig; L. Bauer; V. Lanius; R. Sandbrink; C. Pohl

doi:https://doi.org/10.1016/S1474-4422(09)70237-6

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

L. Kappos, M.S. Freedman, C.H. Polman, G. Edan, H.P. Hartung, D. Miller, X. Montalban, F. Barkhof, E.W. Radu, C. Metzig, L. Bauer, V. Lanius, R. Sandbrink, C. Pohl

Research output: Contribution to journal › Article › Academic › peer-review

324 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	987-997
Journal	Lancet neurology
Volume	8
Issue number	11
DOIs	https://doi.org/10.1016/S1474-4422(09)70237-6
Publication status	Published - 2009

Access to Document

https://doi.org/10.1016/S1474-4422(09)70237-6

Cite this

Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H. P., Miller, D., Montalban, X., Barkhof, F., Radu, E. W., Metzig, C., Bauer, L., Lanius, V., Sandbrink, R., & Pohl, C. (2009). Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet neurology, 8(11), 987-997. https://doi.org/10.1016/S1474-4422(09)70237-6

@article{b51f3bdc02aa46e699fcc3e8c9761083,

title = "Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial",

author = "L. Kappos and M.S. Freedman and C.H. Polman and G. Edan and H.P. Hartung and D. Miller and X. Montalban and F. Barkhof and E.W. Radu and C. Metzig and L. Bauer and V. Lanius and R. Sandbrink and C. Pohl",

year = "2009",

doi = "https://doi.org/10.1016/S1474-4422(09)70237-6",

language = "Undefined/Unknown",

volume = "8",

pages = "987--997",

journal = "Lancet neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "11",

}

Kappos, L, Freedman, MS, Polman, CH, Edan, G, Hartung, HP, Miller, D, Montalban, X, Barkhof, F, Radu, EW, Metzig, C, Bauer, L, Lanius, V, Sandbrink, R & Pohl, C 2009, 'Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial', Lancet neurology, vol. 8, no. 11, pp. 987-997. https://doi.org/10.1016/S1474-4422(09)70237-6

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. / Kappos, L.; Freedman, M.S.; Polman, C.H. et al.
In: Lancet neurology, Vol. 8, No. 11, 2009, p. 987-997.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

AU - Kappos, L.

AU - Freedman, M.S.

AU - Polman, C.H.

AU - Edan, G.

AU - Hartung, H.P.

AU - Miller, D.

AU - Montalban, X.

AU - Barkhof, F.

AU - Radu, E.W.

AU - Metzig, C.

AU - Bauer, L.

AU - Lanius, V.

AU - Sandbrink, R.

AU - Pohl, C.

PY - 2009

Y1 - 2009

U2 - https://doi.org/10.1016/S1474-4422(09)70237-6

DO - https://doi.org/10.1016/S1474-4422(09)70237-6

M3 - Article

SN - 1474-4422

VL - 8

SP - 987

EP - 997

JO - Lancet neurology

JF - Lancet neurology

IS - 11

ER -